C-HQSVGEn1E Lifesciences
dual signal modulators, kinase modulation, AI drug discovery
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HQSV
C-HQSVC-HQSVdual signal modulators, kinase modulation, AI drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
GEn1E Lifesciences dual signal modulators, kinase modulation, AI drug discovery
GEn1E Lifesciences is a clinical-stage Phase 2 company developing first-in-class precision therapies for inflammatory and rare diseases. Its programs target kinase dysregulation involving p38, MK2, and ERK, using selective dual signal modulators rather than traditional kinase inhibitors. The company says its GRID AI platform connects curated public and proprietary data across genes, pathways, proteins, diseases, and compounds to accelerate drug development.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
GEn1E Lifesciences — Translational · Lower middle. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic